ClinicalTrials.gg
RecruitingNCT07143448Updated Oct 30, 2026

A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

A Phase 1/2 interventional study of HS235 and Placebo in Pulmonary Arterial Hypertension, sponsored by 35Pharma Inc., a GSK company. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by 35Pharma Inc., a GSK company · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 30, 2026Sponsor changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Planned enrollment
74th of 253
90 · median 40
Started
2026
with 12 others
Phase 1/2
7 of 312
2 open now
Primary completion
2028-03
later than 34 of 55 live
Registered
298th of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 74th largest by planned enrollment of the 253 interventional ones that give a count, is one of 13 that started in 2026, is one of 7 in phase 1/2, reaches primary completion later than 34 of the 55 other live ones, and was the 298th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)

Read the detailed description

A Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if they meet all of the following criteria:

  1. Male and female participants, 18 years of age and older.
  2. (BMI) 18.5 and 40 kg/m2 and body weight at or below 120 kg.
  3. Baseline RHC performed during the Screening Period documenting:

    1. A minimum PVR of ≥ 5 Wood units (WU) or ≥ 400 dyn·sec·cm-5 and,
    2. A pulmonary artery wedge pressure (PAWP) of ≤ 15 mm Hg.
  4. Diagnosis of WHO pulmonary arterial hypertension (PAH) Group 1.
  5. Symptomatic PAH classified as WHO Functional class II to IV.
  6. On stable doses of at least 2 approved background PAH therapies and diuretics.
  7. 6-Minute Walk Distance (6MWD) ≥ 150 m and ≤ 500 m repeated twice during screening.
  8. Ability to adhere to study visit schedule and understand and comply with all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. PH WHO Groups 2, 3, 4 or 5.
  2. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening.
  3. Any symptomatic coronary disease events.
  4. History of heart transplant or on heart transplant list.
  5. Uncontrolled systemic hypertension.
  6. History of restrictive, constrictive or congestive cardiomyopathy.
  7. History of significant mitral regurgitation or aortic regurgitation valvular disease.
  8. Untreated or poorly controlled moderate or severe obstructive sleep apnea.
  9. A diagnosis of worse than moderate or worse than mild ILD.
  10. Cerebrovascular event within 90 days prior to screening
  11. A pneumonectomy or lobectomy
  12. Having received an activin signaling inhibitor such as sotatercept at any time prior to screening
  13. A > sex-specific
  14. count \< 100,000/mm3
  15. Severe (stage ≥4) renal failure with \< 30 mL/min/m2
  16. Abnormally elevated liver function enzymes ( or AST > 3X ULN, or total > 1.5X ULN).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    HS235

    HS235 Subcutaneous Injection

    Biological: HS235

  • Placebo comparator
    Placebo

    Subcutaneous Injection

    Other: Placebo

Interventions

  • BiologicalHS235

    Subcutaneous Injection

  • OtherPlacebo

    Subcutaneous Injection

06

What researchers measure

Primary outcomes

  1. Incidence and Number of Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participants or clinical trial participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The incidence and number of participants who experience an AE will be reported.

    Time frame: up to 29 weeks

07

Study locations

7 of 7 sites recruiting
  • Investigational Site-102
    Tampa, Florida 33620, United States
    Recruiting
  • Investigational Site-101
    Boston, Massachusetts 02115-6105, United States
    Recruiting
  • Investigational Site-104
    Providence, Rhode Island 02903, United States
    Recruiting
  • Investigational Site-305
    Barcelona, 08035, Spain
    Recruiting
  • Investigational Site- 301
    Barcelona, 8036, Spain
    Recruiting
  • Investigational Site-308
    Madrid, 28041, Spain
    Recruiting
  • Investigational Site-903
    London, W12 0HS, United Kingdom
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Aug 27, 2025
StartActual
Aug 19, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Nov 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed
Show 4 added (2 Spain, 1 United States, 1 United Kingdom)
  • Investigational Site-101 · Boston, United States
  • Investigational Site- 301 · Barcelona, Spain
  • Investigational Site-308 · Madrid, Spain
  • Investigational Site-903 · London, United Kingdom
Show 1 removed
  • Investigational Site-903 · London, United Kingdom
Oct 30, 2026
Sponsor
35Pharma Inc→35Pharma Inc., a GSK company
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    4 sites added, 1 site removed
    Show 4 added (2 Spain, 1 United States, 1 United Kingdom)
    • Investigational Site-101 · Boston, United States
    • Investigational Site- 301 · Barcelona, Spain
    • Investigational Site-308 · Madrid, Spain
    • Investigational Site-903 · London, United Kingdom
    Show 1 removed
    • Investigational Site-903 · London, United Kingdom
    Sponsor 35Pharma Inc→35Pharma Inc., a GSK company
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07143448
Lead sponsor
35Pharma Inc., a GSK company
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 19, 2026
Primary completion
Mar 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS235

Start the discussion